Remicade and Coma hepatic - a phase IV clinical study of FDA data

Summary:

Coma hepatic is reported as a side effect among people who take Remicade (infliximab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Prednisolone, and have Hepatitis alcoholic.

The phase IV clinical study analyzes which people have Coma hepatic when taking Remicade. It is created by eHealthMe based on reports of 222,651 people who have side effects when taking Remicade from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Coma hepatic?

Coma hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma) is found to be associated with 150 drugs and 409 conditions by eHealthMe. Check the latest studies of Coma hepatic.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

222,651 people reported to have side effects when taking Remicade.
Among them, 13 people (0.01%) have Coma hepatic.

Among these 13 people:

How long have people been on Remicade when they have Coma hepatic? *

What is the gender of people who have Coma hepatic when taking Remicade? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Coma hepatic when taking Remicade? *

What are other drugs people take besides Remicade? *

What are other side effects people have besides Coma hepatic? *

Hepatic Failure (liver failure): 5 people, 38.46%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 4 people, 30.77%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 4 people, 30.77%
Duodenal Ulcer Haemorrhage (bleeding duodenal ulcer): 4 people, 30.77%
Cardiac Arrest: 3 people, 23.08%
Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 2 people, 15.38%
Hepatocellular Damage (liver damage): 2 people, 15.38%
Hepatorenal Syndrome (renal failure in patients with advanced chronic liver disease): 2 people, 15.38%
Hypoglycemia (low blood sugar): 2 people, 15.38%
Infection: 2 people, 15.38%

What are the existing conditions these people have? *

Hepatitis Alcoholic (inflammation of the liver due to alcohol): 4 people, 30.77%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 15.38%
Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 7.69%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Coma hepatic?

- Check whether Coma hepatic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remicade:

Remicade (224,011 reports)

Coma hepatic treatments and more:

Coma hepatic (1,279 reports)

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Coma hepatic:

Coma hepatic (150 drugs)

Browse all the conditions that are associated with Coma hepatic:

Coma hepatic (409 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.